Guardant Health, Inc.
NASDAQ Global SelectTotal Valuation
Guardant Health, Inc. carries a market capitalization of 21.66B, placing it among publicly traded companies globally. Its enterprise value stands at 20.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 21.66B |
| Enterprise Value | 20.69B |
Share Statistics
Guardant Health, Inc. currently has 133.61M shares outstanding.
| Shares Outstanding | 133.61M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 16.41, and the price-to-book ratio stands at -89.95.
| PE Ratio | N/A |
| PS Ratio | 16.41 |
| PB Ratio | -89.95 |
| P/TBV Ratio | -61.61 |
| P/FCF Ratio | -149.74 |
| P/OCF Ratio | -104.83 |
Enterprise Valuation
| EV / Sales | 17.49 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Guardant Health, Inc. maintains a current ratio of 4.03, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -761.45, indicating conservative leverage, while an interest coverage ratio of -89.66 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.03 |
| Quick Ratio | 3.53 |
| Debt / Equity | -761.45 |
| Debt / EBITDA | -3.93 |
| Interest Coverage | -89.66 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -27.95 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.37 |
Taxes
| Income Tax | -1.03M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Guardant Health, Inc.'s stock has gained approximately 163.05411% over the past 52 weeks. The 50-day moving average sits at 159.15, while the 200-day moving average is 117.06.
| Beta (5Y) | N/A |
| 52-Week Price Change | 163.05411% |
| 50-Day Moving Average | 159.15 |
| 200-Day Moving Average | 117.06 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guardant Health, Inc. generated 1.18B in revenue and converted that into -453.44M in net income, yielding earnings per share of -3.50. EBITDA reached -431.80M, while operating income came in at -470.26M.
| Revenue | 1.18B |
| Gross Profit | 769.16M |
| Operating Income | -470.26M |
| Pretax Income | -454.47M |
| Net Income | -453.44M |
| EBITDA | -431.80M |
| EBIT | -470.26M |
| Earnings Per Share (EPS) | -3.50 |
Balance Sheet
Guardant Health, Inc. holds 1.05B in cash and equivalents against 1.70B in total debt, resulting in a net debt position of 449.47M. Total book value stands at -222.87M, with working capital of 1.03B providing operational flexibility.
| Cash & Cash Equivalents | 1.05B |
| Total Debt | 1.70B |
| Net Debt | 449.47M |
| Equity (Book Value) | -222.87M |
| Book Value Per Share | -1.67 |
| Working Capital | 1.03B |
Cash Flow
Guardant Health, Inc. produced -185.19M in operating cash flow over the past twelve months. After subtracting -55.54M in capital expenditures, free cash flow totaled -240.72M - equivalent to -1.86 per share.
| Operating Cash Flow | -185.19M |
| Capital Expenditures | -55.54M |
| Free Cash Flow | -240.72M |
| FCF Per Share | -1.86 |
Margins
Guardant Health, Inc. operates with a gross margin of 65.01, reflecting its pricing power and cost economics. The operating margin of -39.75 and net profit margin of -38.33 provide insight into operational efficiency.
| Gross Margin | 65.01 |
| Operating Margin | -39.75 |
| Pretax Margin | -38.41 |
| Profit Margin | -38.33 |
| EBITDA Margin | -36.50 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3.68 |
| FCF Yield | -0.67 |
Scores
Guardant Health, Inc. posts an Altman Z-Score of 3.61, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.61 |